• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Bionano Reports Fourth Quarter and Full-Year 2023 Results and Provides Revenue Outlook for 2024

    3/5/24 4:01:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BNGO alert in real time by email
    • Q4 2023 revenue was $10.7 million, which represents a 30% increase over Q4 2022
    • FY 2023 revenue was $36.1 million, which represents a 30% increase over FY 2022
    • Reached installed base of 326 optical genome mapping (OGM) systems as of YE 2023; increase of 36% over the 240 installed systems as of YE 2022
    • Sold 26,444 nanochannel array flowcells in FY 2023, which represents a 72% increase over the flowcells sold in FY 2022
    • Conference call today, March 5, 2024 at 4:30 PM ET

    SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2023 and revenue outlook for 2024.

    "2023 was a year in which we made tremendous progress toward our mission of transforming the way the world sees the genome. The progress is evidence that our ELEVATE strategy is working," commented Erik Holmlin, PhD, president and chief executive officer of Bionano. "Revenue growth continued with growth of the OGM installed base and consumables units sales. We had a number of significant product launches during 2023, which we believe will make OGM easier to implement and use and make it possible to run substantially more samples. Innovations such as the Stratys™ system for high throughput mapping, and VIA™ software for streamlined visualization, interpretation and reporting of genome analysis results have been enthusiastically received and we expect them to be drivers of revenue growth. We also saw independent confirmation of the utility of our solutions, including the organization of consortia across the world who are driving OGM adoption and implementation. We believe the execution of ELEVATE with the progress of OGM in 2023 and our focus on reducing cash burn, including through new cost savings initiatives introduced today, has well-positioned us for success in 2024."

    Recent Highlights

    • Announced the commercial release of the Stratys system, the Company's system for high throughput OGM, and the completion of the Stratys early access program, which includes 11 systems at 10 customer sites across the globe.
    • Published the first framework paper for the uniform clinical adoption and implementation of the OGM workflow for hematological malignancy applications, authored by an international consortium of 18 researchers. 
    • Published interim readout from second phase of prenatal validation study, which evaluated 342 unique cases for prenatal genetic disease using OGM; results showed OGM to have 100% concordance with traditional cytogenetic methods, with sensitivity of 99.2%, specificity of 100%, and overall accuracy of 99.6%.
    • Published peer-reviewed publication for the second phase of postnatal validation study, which evaluated 627 constitutional postnatal samples using OGM; results showed that 99.5% of samples were fully concordant with standard of care (SOC) methods; when compared to the rate of finding pathogenic or likely pathogenic variants with SOC methods, OGM increased the rate by a factor of 6% to as much as 50% depending on the sample population.
    • Held 2024 Symposium, which featured a record 32 oral presentations and 69 scientific posters from genomic scientists at leading global institutions on the use of OGM for research applications in cancer, genetic disease, and cell and gene therapy. Symposium had over 2,100 registrants from 92 countries and averaged 574 attendees per day.

    Q4 2023 and YE 2023 Highlights

    • Installed base of OGM systems totaled 326 at year-end, which represented a 36% increase over the 240 installed systems reported at the end of 2022.
    • Sold 7,980 nanochannel array flowcells in the fourth quarter and 26,444 flowcells during 2023, which was an increase of 67% over the 4,781 flowcells sold in the fourth quarter of 2022 and an increase of 72% over the 15,375 flowcells sold in 2022.
    • Number of 2023 OGM publications totaled 282, which was a 54% increase over the total number of OGM publications in 2022. Q4 2023 showed the highest number to date of OGM publications in a single quarter with 88 total publications.
    • Since 2021, there have been significant and steady year-over-year percentage increases in the number of OGM publications on research application areas including postnatal and prenatal genetic disorders, hematological malignancies, solid tumors, and cell and gene therapy. Additionally, the number of published human clinical research samples has grown from approximately 500 prior to 2021, to approximately 5,100 as of the end of 2023.

    Achieved All Full-Year 2023 ELEVATE Milestones

    • Released the Stratys system, as part of an early access program in the fourth quarter of 2023. The Stratys system is expected to enable a four-fold increase in raw data generation rate compared to the Saphyr® system and is designed for maximum lab flexibility by enabling up to 12 single access chips, accessible as they complete runs, without the need to batch multiple samples on a consumable.
    • Released VIA software, which replaces NxClinical™ software with a simple and integrated workflow for visualization, interpretation, and reporting for OGM, microarray and NGS data types for enhanced contextualization across multiple variant types and accelerated time to results at a reduced cost. A workflow focused on hematological malignancies was released in June 2023, and in December 2023, the Company announced upgrades to its pipeline for OGM data analysis in VIA software for applications in constitutional genetic diseases.
    • Pre-commercial version of the Ionic® Purification System for isolation of DNA for OGM analysis was running in the field as of the fourth quarter of 2023, with the full commercial launch planned for 2024.
    • Launched an OGM LDT for constitutional genetic disease applications through Bionano Laboratories.
    • Submitted a dossier to Medicare seeking a local coverage determination for OGM coverage.
    • Conducted a pre-submission discussion with FDA in connection with the planned clearance of the Stratys system.
    • Met or exceeded all previously stated 2023 milestones for prenatal, postnatal, and hematological malignancy clinical trials, including: sample enrollment and data collection for prenatal study; interim publication of the prenatal study; interim publication of the hematological malignancy study; peer-reviewed interim publication from postnatal study; and IRB approval for solid tumor study.

    Q4 2023 Financial Results

    • Total revenue for the fourth quarter of 2023 was $10.7 million, an increase of 30% compared to the fourth quarter of 2022.

    • GAAP gross margin for the fourth quarter of 2023 was 23%, which was slightly higher than the 22% GAAP gross margin reported for the fourth quarter of 2022.

    • Fourth quarter 2023 GAAP operating expense was $27.4 million, compared to $39.3 million in the fourth quarter of 2022. The year-over-year decrease was primarily due to a decrease in the fair value of contingent consideration of Purigen milestones and reduced headcount-related expense partly attributed to the cost savings initiatives outlined in our Q2 2023 and Q3 2023 earnings releases.
    • Fourth quarter 2023 non-GAAP operating expense was $27.3 million, compared to $30.6 million in the fourth quarter of 2022.
    • Cash, cash equivalents, and available-for-sale securities as of December 31, 2023 were $102.3 million, of which $35.5 million was subject to certain restrictions.

    FY 2023 Financial Results

    • Full year 2023 revenue was $36.1 million, an increase of 30% compared to 2022.
    • Full year 2023 total gross margin was 26%, up from 21% in 2022.
    • Full year 2023 GAAP operating expense was $224.8 million and non-GAAP operating expense was $127.3 million. Full year 2023 non-GAAP operating expense excludes a one-time impairment charge of $77.3 million, $7.2 million in amortization of intangibles and $14.5 million in stock-based compensation, partially offset by $1.5 million in reductions of contingency based obligations.

    2024 Outlook

    We remain hyper focused on our mission of transforming the way the world sees the genome. To that end we want to highlight the following:

    • We recently amended the convertible debt financing entered into in October 2023 to restructure our debt obligations and we will continue to work with our lender as we manage the remaining obligations.

    • In an effort to streamline our operating structure and focus on core OGM products, we are phasing out First Step and Next Step Dx clinical services products and our Fragile X test, which are legacy, non-OGM tests. In 2023, these products generated around $7.0 million of the overall $36.1 million in revenues. 

    • After taking into account the financial impact of discontinued products, Bionano expects full year 2024 revenue to be in the range of $37.0 to $41.0 million and Q1 2024 revenue is expected to be in the range of $8.25 to $8.75 million.
    • We anticipate installation of 80 to 100 new OGM systems in 2024, with a projected 2024 installed base range of 381 to 401 OGM systems. This range reflects some anticipated Saphyr to Stratys upgrades.

    Cost Savings Initiatives

    • In addition to the cost savings initiatives announced in May and October 2023, we are announcing new plans that will further reduce expenses.
      • With this 2024 initiative, our goal will be reducing annualized operating expense by another estimated $35.0 to $40.0 million, including a potential reduction in headcount by an additional 110 to 125 employees, bringing the total number of employees down to approximately 200 from approximately 324 today.
      • Overall, since May 2023 through the completion of the initiative announced today, we aim to have reduced headcount by approximately 200 people and reduced annualized operating expenses by about $65.0 to $75.0 million.
    • We expect to continue exploring strategic opportunities that we believe will maximize stakeholder value. These opportunities could include any of the following or a combination thereof: debt financing, equity investments, combinations with other companies, or the sale of all or part of the company. There can be no assurances that any transactions will be completed, and we do not intend to disclose or comment on interim developments except to the extent required by law.
    • We believe these activities will allow us to remain committed to our customers and partners, and to be able to continue expanding the opportunity and availability of OGM.

    "We started 2024 with a focus on addressing cash burn and financial discipline, and we continue to take actions that we believe will enable us to improve margins and further extend our cash runway, including through the cost savings initiatives announced today and the amended debt financing agreement we announced last week. I am pleased to see that our 2023 cost savings initiatives have started to have a positive impact on our operating expenses and expect to see continued progress in that area over the course of the year," added Gülsen Kama, chief financial officer of Bionano.

    Webcast Details

    Webcast Details
    Date:Tuesday, March 5, 2024
    Time:4:30 p.m. Eastern Time
    Participant Registration:https://register.vevent.com/register/BI54a6f64eeb2842bd893b4ad1b52fc78f 
    Webcast:https://edge.media-server.com/mmc/p/afaym86g/ 



    Participants should register at the link above in advance of the call, and then click the webcast link before the call begins. An archived version of the webcast will be available for replay in the Investors section of the Bionano website.

    About Bionano

    Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company's mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. The Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. For more information, visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.

    Bionano's OGM products are for research use only and not for use in diagnostic procedures.

    Non-GAAP Financial Measures

    To supplement Bionano's financial results reported in accordance with U.S. generally accepted accounting principles (GAAP), the Company has provided non-GAAP operating expense in this press release and the accompanying conference call, which is a non-GAAP financial measure. Non-GAAP operating expense excludes from GAAP reported operating expense the following components as detailed in the reconciliation table accompanying this press release: stock-based compensation, amortization of intangibles and acquisition-related expenses.

    Bionano believes that non-GAAP operating expense is useful to investors and analysts as a supplement to its financial information prepared in accordance with GAAP for analyzing operating performance and identifying operating trends in its business. Bionano uses non-GAAP operating expense internally to facilitate period-to-period comparisons and analysis of its operating performance in order to understand, manage and evaluate its business and to make operating decisions. Accordingly, Bionano believes this measure allows for greater transparency with respect to key financial metrics it uses in assessing its own operating performance and making operating decisions.

    This non-GAAP financial measure is not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP; has no standardized meaning prescribed by GAAP; and is not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future, there may be other items that the Company may exclude for purposes of its non-GAAP financial measures; and the Company may in the future cease to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. Likewise, the Company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measure as used by Bionano in this press release and the accompanying reconciliation table has limits in its usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.

    For a reconciliation of non-GAAP operating expense to operating expense reported in accordance with GAAP, please refer to the financial tables accompanying this press release.

    Forward-Looking Statements of Bionano Genomics

    This press release and the accompanying conference call contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. Words such as "anticipate", "believe," "could", "estimate," "expect," "intend," "may," "plan," "potential", "predict," "project," "should," "target," "will," or "would" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our expectations regarding product uptake, revenue growth, market development and increased OGM adoption, including through publications highlighting the utility and applications of OGM; our growth prospects and future financial and operating results, including our 2024 revenue guidance, expected impact from our cost savings initiatives and plans to reduce our annualized cost structure and the timing for such savings; the growth of our installed base of OGM systems; our expectation that innovations such as the Stratys system and VIA software will be drivers of future growth, the sales of our flowcell consumables and the other expectations related thereto; our ability to meet our stated goals, including to drive value and penetrate into our target markets; our commercial expectations, including the potential market opportunity for structural variation analysis and OGM; the impact on our commercial opportunities related to the launch of our next-generation OGM system and our analysis software; continued research, presentations and publications involving OGM, its utility compared to traditional cytogenetics and our technologies; our ability to drive adoption of OGM and our technology solutions; and expected timing and results from our clinical studies; our exploring a variety of strategic opportunities that we believe will maximize stakeholder value and the execution of our strategy. Each of these forward-looking statements involves risks and uncertainties. Accordingly, investors and prospective investors are cautioned not to place undue reliance on these forward-looking statements as they involve inherent risk and uncertainty (both general and specific) and should note that they are provided as a general guide only and should not be relied on as an indication or guarantee of future performance. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the timing and amount of revenue we are able to recognize in a given fiscal period; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts and our ability to continue as a "going concern"; the impact of adverse geopolitical and macroeconomic events, such as the ongoing conflicts between Ukraine and Russia and Israel and Gaza and uncertain market conditions, including inflation and supply chain disruptions, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; changes in our strategic and commercial plans; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; study results that differ or contradict the results mentioned in this press release; the risk that we are not able to complete a strategic transaction that would increase stakeholder value; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2022 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

    CONTACTS

    Company Contact:

    Erik Holmlin, CEO

    Bionano Genomics, Inc.

    +1 (858) 888-7610

    [email protected]

    Investor Relations:

    David R. Holmes

    Gilmartin Group

    +1 (858) 366-3243

    [email protected]      

     

     
    BIONANO GENOMICS, INC
    Consolidated Statement of Operations
     Three Months Ended December 31, Years Ended December 31,
      2023   2022   2023   2022 
    Revenue:       
    Product revenue$8,215,000  $6,171,000  $26,727,000  $20,425,000 
    Service and other revenue 2,506,000   2,044,000   9,389,000   7,377,000 
    Total revenue 10,721,000   8,215,000   36,116,000   27,802,000 
    Cost of revenue:       
    Cost of product revenue 6,701,000   4,709,000   20,415,000   15,966,000 
    Cost of service and other revenue 1,582,000   1,701,000   6,135,000   5,891,000 
    Total cost of revenue 8,283,000   6,410,000   26,550,000   21,857,000 
    Operating expenses:       
    Research and development 11,701,000   14,011,000   54,032,000   49,047,000 
    Selling, general and administrative 15,690,000   25,321,000   93,499,000   88,596,000 
    Goodwill Impairment —   —   77,280,000   — 
    Total operating expenses 27,391,000   39,332,000   224,811,000   137,643,000 
    Loss from operations (24,953,000)  (37,527,000)  (215,245,000)  (131,698,000)
    Other income (expenses)       
    Interest income 1,189,000   770,000   3,311,000   1,507,000 
    Interest expense (4,898,000)  (75,000)  (5,119,000)  (298,000)
    Other income (expenses) 3,562,000   (40,000)  3,449,000   (223,000)
    Loss on convertible note payable (18,827,000)  —   (18,827,000)  — 
    Total other income (expenses) (18,974,000)  655,000   (17,186,000)  986,000 
    Loss before income taxes (43,927,000)  (36,872,000)  (232,431,000)  (130,712,000)
    Benefit (provision) for income taxes 36,000   (1,805,000)  (62,000)  (1,884,000)
    Net loss$(43,891,000) $(38,677,000) $(232,493,000) $(132,596,000)



     
    BIONANO GENOMICS, INC
    Consolidated Balance Sheet
     December 31,
      2023   2022 
        
    Assets   
    Current assets:   
    Cash and cash equivalents$17,948,000  $5,091,000 
    Investments 48,823,000   108,095,000 
    Accounts receivable, net 9,319,000   7,022,000 
    Inventory 22,892,000   29,761,000 
    Prepaid expenses and other current assets 6,019,000   7,329,000 
    Restricted investments 35,117,000   — 
    Total current assets 140,118,000   157,298,000 
    Restricted cash 400,000   400,000 
    Property and equipment, net 23,345,000   18,029,000 
    Operating lease right-of-use assets 5,633,000   7,222,000 
    Financing lease right-of-use assets, related party 3,503,000   3,707,000 
    Intangible assets, net 33,974,000   41,143,000 
    Goodwill —   77,289,000 
    Other long-term assets 7,431,000   2,414,000 
    Total assets$214,404,000  $307,502,000 
    Liabilities and stockholders' equity   
    Current liabilities:   
    Accounts payable$10,384,000  $12,534,000 
    Accrued expenses 8,089,000   10,552,000 
    Contract liabilities 783,000   871,000 
    Short term operating lease liability 2,163,000   2,260,000 
    Short term finance lease liability 272,000   285,000 
    Contingent consideration, short term —   9,382,000 
    Purchase option liability (at fair value) 8,534,000   — 
    Convertible notes payable (at fair value) 69,803,000   — 
    Total current liabilities 100,028,000   35,884,000 
    Operating lease liability, net of current portion 3,590,000   5,504,000 
    Finance lease liability, net of current portion 3,585,000   3,619,000 
    Contingent consideration 10,890,000   12,970,000 
    Long-term contract liabilities 154,000   127,000 
    Total liabilities$118,247,000  $58,104,000 
    Stockholders' equity:   
    Common Stock 5,000   3,000 
    Additional paid-in capital 677,337,000   599,234,000 
    Accumulated deficit (581,208,000)  (348,715,000)
    Accumulated other comprehensive loss 23,000   (1,124,000)
    Total stockholders' equity 96,157,000   249,398,000 
    Total liabilities and stockholders' equity$214,404,000  $307,502,000 



     
    Bionano Genomics, Inc.
    Reconciliation of GAAP Operating Expense to Non-GAAP Operating Expense (Unaudited)
     Three Months Ended December 31, Years Ended December 31,
      2023   2022   2023   2022 
    GAAP gross margin:       
    GAAP revenue$10,721,000  $8,215,000  $36,116,000  $27,802,000 
    GAAP cost of revenue 8,283,000   6,410,000   26,550,000   21,857,000 
    GAAP gross profit 2,438,000   1,805,000   9,566,000   5,945,000 
    GAAP gross margin % 23%  22%  26%  21%
            
    Adjusted non-GAAP gross margin:       
    GAAP revenue$10,721,000  $8,215,000  $36,116,000  $27,802,000 
    GAAP cost of revenue 8,283,000   6,410,000   26,550,000   21,857,000 
    Stock-based compensation expense (172,000)  —   (703,000)  — 
    Adjusted non-GAAP cost of revenue 8,111,000   6,410,000   25,847,000   21,857,000 
    Adjusted non-GAAP gross profit 2,610,000   1,805,000   10,269,000   5,945,000 
    Adjusted non-GAAP gross margin % 24%  22%  28%  21%
            
    GAAP operating expense       
    GAAP selling, general and administrative expense$15,690,000  $25,321,000  $93,499,000  $88,596,000 
    Stock-based compensation expense (2,015,000)  (2,478,000)  (9,383,000)  (9,015,000)
    Intangible asset amortization (1,792,000)  (1,543,000)  (7,169,000)  (5,800,000)
    Change in fair value of contingent consideration 3,990,000   (79,000)  1,462,000   (316,000)
    Transaction related expenses$929,000  $(1,673,000) $—  $(1,760,000)
    Adjusted non-GAAP selling, general and administrative expense 16,802,000   19,548,000   78,409,000   71,705,000 
    GAAP research and development expense$11,701,000  $14,011,000  $54,032,000  $49,047,000 
    Stock-based compensation expense (1,185,000)  (3,001,000)  (5,092,000)  (13,402,000)
    Adjusted non-GAAP research and development expense 10,516,000   11,010,000   48,940,000   35,645,000 
    GAAP goodwill impairment loss$—  $—  $77,280,000  $— 
    Goodwill impairment loss$—  $—  $(77,280,000) $— 
    Adjusted non-GAAP goodwill impairment loss$—  $—  $—  $— 
    Total adjusted non-GAAP operating expense$27,318,000  $30,558,000  $127,349,000  $107,350,000 







    Primary Logo

    Get the next $BNGO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BNGO

    DatePrice TargetRatingAnalyst
    11/15/2024Buy → Neutral
    Ladenburg Thalmann
    9/10/2024Buy → Neutral
    BTIG Research
    1/5/2023$4.00Sector Outperform
    Scotiabank
    12/12/2022$3.50Buy
    BTIG Research
    7/18/2022$12.00Outperform
    Oppenheimer
    More analyst ratings

    $BNGO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Bionano Genomics Inc.

      10-Q - Bionano Genomics, Inc. (0001411690) (Filer)

      5/14/25 4:11:22 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bionano Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Bionano Genomics, Inc. (0001411690) (Filer)

      5/14/25 4:09:51 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEFA14A filed by Bionano Genomics Inc.

      DEFA14A - Bionano Genomics, Inc. (0001411690) (Filer)

      4/28/25 4:17:17 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BNGO
    Financials

    Live finance-specific insights

    See more
    • Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025

      SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, May 14th, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:https://edge.media-server.com/mmc/p/vncjmqc9 Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at https://ir.b

      5/7/25 4:01:00 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bionano to Report Fourth Quarter and Full Year 2024 Financial Results and Host a Conference Call Webcast on March 31, 2025

      SAN DIEGO, March 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Monday, March 31, 2025, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and full year 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Monday, March 31st, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/5v2s5x5r Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website

      3/14/25 8:00:00 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bionano to Report Third Quarter 2024 Financial Results and Host a Conference Call and Webcast on November 13, 2024

      SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 13, 2024, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, November 13th, 2024Time:4:30 p.m. ETParticipant Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/dmabxin9 Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at h

      11/7/24 4:01:00 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BNGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bionano Genomics downgraded by Ladenburg Thalmann

      Ladenburg Thalmann downgraded Bionano Genomics from Buy to Neutral

      11/15/24 7:40:01 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bionano Genomics downgraded by BTIG Research

      BTIG Research downgraded Bionano Genomics from Buy to Neutral

      9/10/24 7:37:53 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Scotiabank initiated coverage on Bionano Genomics with a new price target

      Scotiabank initiated coverage of Bionano Genomics with a rating of Sector Outperform and set a new price target of $4.00

      1/5/23 7:29:54 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BNGO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bionano Laboratories Announces a Second Category I CPT Code for OGM Established by the AMA; this one for Use in Whole Genome Analysis for Constitutional Genetic Disorders

      SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASDAQ:BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced that the editorial panel of the American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT®) code for the use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations related to constitutional genetic disorders. The CPT code is a key component in obtaining reimbursement for the OGM-Dx™ Postnatal Whole Genome SV and OGM-Dx™ Prenatal Whole Genome SV LDTs from third party pay

      5/19/25 8:00:00 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress

      SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the first quarter ended March 31, 2025. "The first quarter of 2025 represents the first full quarter of execution after shifting strategy towards a focus on our base of routine users of optical genome mapping (OGM) and VIA™ software as the primary drivers of our revenue and gross profit.   We are pleased to see consistent utilization of our OGM systems and software combined with a year-over-year growth in consumables purchased by our customers we consider to be routine users of OGM. After significant reductions in costs and cash burn, together with our gross margin improve

      5/14/25 4:01:00 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bionano Laboratories Announces Publication of the Largest Study To-Date Evaluating Clinical Utility of Optical Genome Mapping Across Multiple Hematologic Malignancies

      In 58% or 303 of 519 cases, optical genome mapping (OGM) revealed somatic aberrations that were not detected by the standard cytogenetic workup (SCGW), including Tier 1, Tier 2 and Tier 3 structural variants (SVs) and copy number variants (CNVs)In 15% or 75 of 519 cases, OGM identified additional Tier 1 variants with detection rates varying by disease type, ranging from 52% in T-ALL to 0% in MPN. Every Tier 1 SV or CNV detected by OGM had direct diagnostic, prognostic, or therapeutic significance, meaning that the detection would provide additional clinical utility SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASD

      5/13/25 8:00:00 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BNGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

      SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)

      2/13/24 5:00:51 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

      SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)

      7/7/23 4:35:55 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

      SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)

      1/30/23 4:03:23 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BNGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by General Counsel Dixon Jonathan V.

      4 - Bionano Genomics, Inc. (0001411690) (Issuer)

      3/18/25 6:45:55 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Principal Accounting Officer Adamchak Mark

      4 - Bionano Genomics, Inc. (0001411690) (Issuer)

      3/18/25 6:45:45 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • President and CEO Holmlin R. Erik covered exercise/tax liability with 198 shares, decreasing direct ownership by 10% to 1,783 units (SEC Form 4)

      4 - Bionano Genomics, Inc. (0001411690) (Issuer)

      3/18/25 6:45:35 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BNGO
    Leadership Updates

    Live Leadership Updates

    See more
    • LeddarTech Appoints Chris Stewart as Chief Financial Officer

      QUEBEC CITY, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- LeddarTech®, an automotive software company that provides patented disruptive low-level sensor fusion and perception software technology for ADAS and AD, proudly announces the appointment of Mr. Chris Stewart as Chief Financial Officer ("CFO"). As CFO at LeddarTech, Mr. Stewart will be instrumental in supporting LeddarTech in completing its recently announced business combination with Prospector Capital Corp. and transitioning to a publicly traded company. Mr. Stewart has over 20 years of financial management experience at companies ranging from startups to large public companies. Mr. Stewart previously served as the Chief Financial

      11/15/23 12:07:00 AM ET
      $BNGO
      $PRSR
      $TSLA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Blank Checks
      Finance
    • Bionano Announces CFO Transition and Appointment of Gülsen Kama as Chief Financial Officer

      SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023. Christopher Stewart, who held the position of CFO since September 2020, will stay on during the transition and then move into an advisory role. Ms. Kama has an extensive background in business planning and execution, especially in operating environments that demand rigorous management of expenses to enable profitable growth. She was most recently Chief Financial Officer at Northern Data AG, where she created and implemented a global finance organization to enable strong growth. Prior to Northe

      8/14/23 8:00:00 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bionano Genomics Appoints Donna Polizio as Its First Ever Global Head of Market Access

      SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it has appointed Donna Polizio as its global head of market access, further strengthening its leadership team. The appointment of a global head of market access reflects Bionano's focus on advancing the adoption of optical genome mapping (OGM) and working to meet market needs. Ms. Polizio was most recently the vice president of U.S. managed care and reimbursement at Genomic Health, acquired by Exact Sciences in 2019. In this role, she managed payor contracting and reimbursements that helped drive profitability of Genomic Health prior to its acquisition. Ms. Polizio has also held senior l

      11/10/22 8:00:00 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials